Anticancer Drugs Larotrectinib Medicine Oncology Pharmacology Physiotherapy

Larotrectinib (Mechanism of Action)

In this article we will discuss Larotrectinib (Mechanism of Action)

In this article, we will discuss Larotrectinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM. One other kinase TNK2 was inhibited at
approximately 100-fold higher concentration. TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3.Chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines.

In in vitro and in vivo tumor models, larotrectinib demonstrated anti-tumor activity in cells with constitutive activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK protein overexpression. Larotrectinib had minimal activity in cell lines with point mutations in the TRKA kinase domain, including the clinically identified acquired resistance mutation, G595R. Point mutations in the TRKC kinase domain with clinically identified acquired resistance to larotrectinib include G623R, G696A, and F617L.


Cardiac Electrophysiology
At a dose 9-fold higher than the recommended adult dose, Larotrectinib does not prolong QTc intervals to any clinically relevant extent.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.